| Name | Title | Contact Details |
|---|
Warm Springs Rehabilitation System is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Warm Springs Rehabilitation System is based in San Antonio, TX. You can find more information on Warm Springs Rehabilitation System at www.warmsprings.org
DAKO is a fully integrated, global provider of cancer diagnostic and research products for pathology and oncology. The Company's products utilize antibodies, nucleic acid probes, and proprietary detection technologies to identify specific
Conventional approaches aren't getting the job done so we've taken a whole new approach to helping individuals make more informed, confident choices. We've built a company for the sole purpose of engaging and delighting your employees and supporting them with every health benefits or healthcare question they have. We've proven that by giving employees and their families a great service and helping them get the right care that we can create more satisfied and committed employees and lower healthcare costs for employers. We've aligned our people, processes and technology to do the hard work of simplifying healthcare. We partner with large, innovative and forward-thinking organizations that share the belief that taking care of their employees when they need it most, is good for their business.
NYU Langone Medical Center is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in New York, NY. To find more information about NYU Langone Medical Center, please visit www.nyumc.org
Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.